Xintao Qiu
Xintao Qiu
Harvard Medical School / Dana Faber Cancer Institute
Dirección de correo verificada de
Citado por
Citado por
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
D Pan, A Kobayashi, P Jiang, L Ferrari de Andrade, RE Tay, AM Luoma, ...
Science 359 (6377), 770-775, 2018
A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer
DY Takeda, S Spisák, JH Seo, C Bell, E O’Connor, K Korthauer, D Ribli, ...
Cell 174 (2), 422-432. e13, 2018
Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations
R Jeselsohn, JS Bergholz, M Pun, MI Cornwell, W Liu, A Nardone, T Xiao, ...
Cancer cell 33 (2), 173-186. e5, 2018
Prostate cancer reactivates developmental epigenomic programs during metastatic progression
MM Pomerantz, X Qiu, Y Zhu, DY Takeda, W Pan, SC Baca, A Gusev, ...
Nature genetics 52 (8), 790-799, 2020
VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis
MI Cornwell, M Vangala, L Taing, Z Herbert, J Köster, B Li, H Sun, T Li, ...
BMC bioinformatics 19, 1-14, 2018
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer
KL Morel, AV Sheahan, DL Burkhart, SC Baca, N Boufaied, Y Liu, X Qiu, ...
Nature cancer 2 (4), 444-456, 2021
Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer
S Shu, HJ Wu, YG Jennifer, R Zeid, IS Harris, B Jovanović, K Murphy, ...
Molecular cell 78 (6), 1096-1113. e8, 2020
Integrative analyses of single-cell transcriptome and regulome using MAESTRO
C Wang, D Sun, X Huang, C Wan, Z Li, Y Han, Q Qin, J Fan, X Qiu, Y Xie, ...
Genome biology 21, 1-28, 2020
A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2)
YZ Mazzu, J Armenia, G Chakraborty, Y Yoshikawa, SAA Coggins, ...
Clinical Cancer Research 25 (14), 4480-4492, 2019
Targetable vulnerabilities in T-and NK-cell lymphomas identified through preclinical models
SY Ng, N Yoshida, AL Christie, M Ghandi, NV Dharia, J Dempster, ...
Nature communications 9 (1), 2024, 2018
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
SC Baca, DY Takeda, JH Seo, J Hwang, SY Ku, R Arafeh, T Arnoff, ...
Nature communications 12 (1), 1979, 2021
Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer
P Cejas, Y Xie, A Font-Tello, K Lim, S Syamala, X Qiu, AK Tewari, N Shah, ...
Nature communications 12 (1), 5775, 2021
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets
X Qiu, N Boufaied, T Hallal, A Feit, A de Polo, AM Luoma, W Alahmadi, ...
Nature communications 13 (1), 2559, 2022
Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling
H Singhal, ME Greene, AL Zarnke, M Laine, R Al Abosy, YF Chang, ...
Oncotarget 9 (4), 4282, 2018
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity
AC Watt, P Cejas, MJ DeCristo, O Metzger-Filho, EYN Lam, X Qiu, ...
Nature Cancer 2 (1), 34-48, 2021
CREB5 promotes resistance to androgen-receptor antagonists and androgen deprivation in prostate cancer
JH Hwang, JH Seo, ML Beshiri, S Wankowicz, D Liu, A Cheung, J Li, ...
Cell reports 29 (8), 2355-2370. e6, 2019
Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ
L Ding, Y Su, A Fassl, K Hinohara, X Qiu, NW Harper, SJ Huh, ...
Nature communications 10 (1), 4182, 2019
TRPS1 is a lineage-specific transcriptional dependency in breast cancer
RM Witwicki, MB Ekram, X Qiu, M Janiszewska, S Shu, M Kwon, A Trinh, ...
Cell reports 25 (5), 1255-1267. e5, 2018
Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence
Z Wu, J Zhou, X Zhang, Z Zhang, Y Xie, J Liu, ZV Ho, A Panda, X Qiu, ...
Nature genetics 53 (6), 881-894, 2021
Androgen receptor is a non-canonical inhibitor of wild-type and mutant estrogen receptors in hormone receptor-positive breast cancers
S Ponnusamy, S Asemota, LS Schwartzberg, F Guestini, KM McNamara, ...
Iscience 21, 341-358, 2019
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20